# VBI Vaccines

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/vbi-vaccines

- Industry: Biotechnology
- Headquarters: Cambridge, US
- Website: www.vbivaccines.com
- Total disclosed funding: $36M
- Latest round: Series A (Jan 4, 2007)
- Investors on record: 3

## About

VBI Vaccines Inc. is a biotechnology company focused on developing innovative vaccine and immunotherapeutic candidates aimed at enhancing the immune response against infectious diseases and cancers.Founded in 2001, VBI Vaccines Inc. operates out of Cambridge, US, specializing in vaccine development. The company went public in February 2012 and has completed 19 deals to date. The current CEO is Jeffrey Baxter, while Kelley Carson is also noted in leadership. VBI has raised a total of USD 70.00 mn, with its latest funding round being Venture Debt, amounting to USD 100.00 mn.VBI Vaccines Inc. specializes in developing innovative vaccine and immunotherapeutic candidates designed to enhance the human immune system's ability to prevent and combat significant infectious diseases and aggressive cancers. The company's primary product offerings leverage virus-like particle (VLP) technology, closely mimicking the natural presentation of viruses to elicit robust immune responses. Their flagship products include vaccine candidates targeting highly contagious infectious diseases and fast-growing cancers, addressing significant unmet public health needs on a global scale. VBI's products are designed for a diverse client base, including healthcare providers, governments, and research institutions, targeting markets across North America, Europe, and other regions where public health challenges related to infectious diseases and cancer are prevalent.In 2023, VBI Vaccines reported revenue of USD 8.68 mn, while experiencing an EBITDA loss of USD 77.92 mn. The company generates revenue through partnerships and collaborations with various stakeholders in the healthcare ecosystem, including governmental agencies, research institutions, and pharmaceutical companies. These collaborations typically involve B2B agreements for clinical trials and development, potentially leading to licensing agreements or co-development arrangements.VBI Vaccines Inc. aims to enhance its product offerings with new vaccine candidates designed to address emerging infectious diseases and cancer types. The company is exploring expansion opportunities into European and Asian markets, with plans to launch these initiatives by 2025. The recent Venture Debt funding of USD 100.00 mn will support the development of new products and facilitate entry into these new geographic regions.

## Funding rounds

- Series A, Jan 4, 2007, $36M — ARCH Venture Partners, 5AM Ventures, Clarus Ventures

## Investors

- ARCH Venture Partners (https://capitalatlas.ai/funds/arch-venture-partners) — Series A
- 5AM Ventures (https://capitalatlas.ai/funds/5am-ventures) — Series A
- Clarus Ventures (https://capitalatlas.ai/funds/clarus-ventures) — Series A